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Abstract
Purpose To determine the value of prebiopsy 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/com-
puted tomography (CT) in discriminating malignant from benign vertebral bone lesions.
Materials and methods This retrospective study included 53 patients with 55 vertebral bone lesions that underwent FDG-PET/
CT before CT-guided biopsy. Pathologic examination of the biopsy sample and a minimum follow-up of 1 year were used as
reference standard.
Results Sensitivity, specificity, positive predictive value, and negative predictive value of visual FDG-PET analysis (with lesion
FDG uptake higher than liver FDG uptake as threshold for malignancy) in discriminating malignant from benign vertebral bone
lesions were 91.3% (42/46), 22.2% (2/9), 85.7% (42/49), and 33.3% (2/6), respectively. The semiquantitative FDG-PET metrics
SUVmax and SUVpeak achieved areas under the receiver operating characteristics curve of 0.630 and 0.671, respectively.
Malignant lesions demonstrated bone lysis more frequently than benign lesions (60.9% (28/46) vs. 22.2% (2/9)), and this
difference was nearly significant (P = 0.064). All other clinical and conventional imaging characteristics (including patient
age, gender, previous diagnosis of malignancy, bone pain, weight loss, any CT abnormality, sclerosis, cortical destruction, bone
marrow replacement, associated extraosseous soft tissue mass, and accompanying vertebral height loss, multiple bone lesions on
FDG-PET/CT, and suspicious extraosseous lesions on FDG-PET/CT) were not significantly different (P = 0.143 to 1.000).
Conclusion FDG-PET/CT may steer the diagnosis (particularly thanks to a relatively high PPV and value of semiquantitative
measurements), but cannot always classify vertebral bone lesions as malignant or benign with sufficient certainty. In these cases,
biopsy and/or follow-up remain necessary to establish a final diagnosis.
Keywords 18F-FDG . Biopsy . Bone . PET-CT . Spine .
Vertebra
Introduction
Bone metastases are a frequent complication of cancer [1].
Importantly, the spine is the most common site of bone me-
tastasis [2]. It has been reported that over 10% of patients with
cancer develop a symptomatic spinal metastasis [2].
Meanwhile, there is also a wide spectrum of primary malig-
nant tumors, benign tumors, and tumor-simulating lesions
(e.g., infections and fractures) that can occur in the spine [3,
4].
If the combination of clinical and imaging characteristics is
not specific for a clinically irrelevant benign spinal lesion such
as a simple hemangioma, bone island, or Schmörl’s node, or
another benign entity such as infection or fracture, percutane-
ous computed tomography (CT)-guided biopsy is often
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performed with the aim to establish a diagnosis. The diagnos-
tic yield of CT-guided biopsy in the spine has been reported to
range between approximately 60 and 80% [5–7] and to be
lower than in other parts of the skeletal system [5, 6]. This is
most likely due to the relatively smaller size of the vertebrae
and to the difficulties in obtaining more than one biopsy core
in this location [5]. Furthermore, overall complication rate of
CT-guided biopsy in the spine is approximately 3% [8], with
nerve root damage, local infection, pneumothorax, vascular
injury, paraspinal hematoma, temporary paresis, paraplegia,
meningitis, and even death among the spectrum of complica-
tions that may occur [7]. In addition, patients with spinal le-
sions may have pain and dyspnea and may not be able to lie
still for the procedure to be successfully performed [9].
Although CT-guided biopsy remains indispensable in the di-
agnostic work-up of spinal lesions, its limitations and disad-
vantages indicate the need for ancillary noninvasive diagnos-
tic methods for lesion characterization.
The noninvasive characterization of spinal lesions tradi-
tionally relies on structural patterns as seen on CT and mag-
netic resonance imaging (MRI) [3, 4]. Meanwhile, positron
emission tomography (PET)/CT with the radiotracer 18F-
fluoro-2-deoxy-D-glucose (FDG) is increasingly used in clin-
ical practice [10]. FDG-PET provides information on lesion
glucose metabolism, which goes beyond anatomical imaging
[10]. However, there is a lack of data on its use for the eval-
uation of spinal lesions. It can be hypothesized that FDG up-
take is higher in malignant than in benign spinal lesions, and
that the need for vertebral biopsy in every patient can be
reconsidered if FDG-PET/CT proves to achieve a high dis-
criminatory performance in this setting.
The aim of this study was therefore to determine the diag-
nostic performance of prebiopsy FDG-PET/CT for the dis-
crimination between malignant and benign vertebral bone
lesions.
Materials and methods
Study design
This study was approved by the local institutional review
board (IRB number 201800105), and because of its retrospec-
tive design, the requirement for informed consent was waived.
The electronic patient database of our university hospital
(University Medical Center Groningen, Groningen, the
Netherlands) was searched for all patients who had an FDG-
PET/CT scan within 2 months before CT-guided bone biopsy
of a vertebral bone lesion, within a consecutive 8-year period
(from August 2010 to September 2018). Lesions that were
b iops ied because of a pr ior i h igh susp ic ion of
spondylodiscitis, and lesions whose nature remained unclear
even after biopsy and follow-up (see the “Reference standard”
section), were excluded.
FDG-PET/CT acquisition
All FDG-PET/CT scans were performed using an integrated
PET/CT system (Biograph mCT 40- or 64-slice PET/CT,
Siemens Healthineers, Erlangen, Germany). All patients
fasted for at least 6 h and blood glucose levels were checked
to be less than 11 mmol/L before 3MBq FDG/kg body weight
was intravenously administered. After approximately 60 min,
low-dose unenhanced CT scanning (with 100 kV and an av-
erage tube current of 90 mAs) was performed for attenuation
correction and anatomic correlation. Subsequently, 3D PET
scanning was performed from mid-thigh to top of the skull
using a multi-bed position approach (5 to 7 bed positions with
3 min per bed position). FDG-PET/CT acquisition and recon-
struction were in line with the European Association of
Nuclear Medicine/Research 4 Life guidelines [11].
FDG-PET/CT evaluation
All FDG-PET/CT scans were interpreted by nuclear medicine
physicians as part of standard clinical care. A research fellow
(N.L.), supervised by a nuclear medicine physician
(A.W.J.M.G), reviewed all FDG-PET/CT scans using a dedi-
cated workstation with the Syngo.via software (Siemens
Healthineers, Erlangen, Germany). This reader knew the lo-
cation of each biopsied vertebral lesion, but was blinded to all
other clinical, imaging, pathological, and follow-up findings.
FDG uptake of all biopsied vertebral bone lesions was both
visually and semiquantitatively assessed. Visual assessment
was done using a four-point grading scale (1, no FDG uptake;
2, slight FDG uptake but less than mediastinal FDG accumu-
lation; 3, FDG uptake higher than mediastinal FDG accumu-
lation but lower than or equal to liver FDG uptake; 4, FDG
uptake higher than liver FDG uptake). Quantitative assess-
ment was done with (glucose corrected) maximum standard-
ized uptake value (SUVmax, representing the value of the sin-
gle voxel with the highest SUV) and peak standardized uptake
value (SUVpeak, representing the mean SUV of a 12-mm di-
ameter sphere encompassing the SUVmax) measurements.
CT-guided biopsy
Each vertebral bone lesion was biopsied under CT guidance
by one of six musculoskeletal radiologists, as part of standard
clinical care. Prebiopsy full-dose unenhanced CT (with 100–
140 kV, and automatic dose modulation) was always per-
formed to plan the biopsy route towards the lesion. One core
biopsy was obtained from each lesion, with needle sizes rang-
ing between 8 and 18 gauge, depending on the choice of the
radiologist. Multislice CT systems (Somatom Sensation 16 or
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Definition 64 AS, Siemens Healthineers, Erlangen, Germany)
and 8-gauge biopsy (Snarecoil, Ranfac, Avon,MA, USA), 11-
gauge battery-powered biopsy (Arrow OnControl, Teleflex,
Shavano Park, TX, USA), and 16- and 18-gauge biopsy
(BioPince, ArgonMedical Devices, Frisco, TX, USA) devices
were used in this study.
CT evaluation
Each vertebral bone lesion was reviewed on prebiopsy plan-
ning CT by a musculoskeletal radiologist (T.C.K.) using a
dedicated workstation (Carestream Vue PACS, version
11.4.1.1102, Carestream Health, Rochester, NY, USA). This
reader knew the location of each biopsied vertebral bone le-
sion, but was blinded to all other clinical, imaging, patholog-
ical, and follow-up findings. Reconstructed 2.0-mm axial, cor-
onal, and sagittal CT images were reviewed in bone window
(level, 700 HU; width, 3000 HU) and soft tissue (level,
40 HU; width, 500 HU) settings. The location of each lesion
was first assessed for the presence of any CT abnormality. If
this was the case, the lesion was then assessed for the presence
or absence of lysis, sclerosis, cortical destruction, bone mar-
row replacement, associated extraosseous soft tissue mass,
and accompanying vertebral height loss.
Reference standard
The nature of each vertebral bone lesion was classified as
malignant or benign based on the CT-guided biopsy sample,
which was examined by a specialized musculoskeletal pathol-
ogist in each case. If the nature of the lesion could not be
established with certainty based on the biopsy result, all avail-
able follow-up examinations (including subsequent tissue
samplings, clinical and imaging tests) were used to determine
whether the lesion of interest was malignant or benign. A
lesion was considered malignant if a subsequent tissue sam-
pling revealed malignancy. A lesion was considered benign if
it remained stable or regressed with conservative treatment
during a follow-up period of at least 1 year. The nature of all
other vertebral bone lesions was considered unclear.
Statistical analysis
Sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) of FDG-PET/CT in discrim-
inating malignant from benign vertebral bone lesions were
calculated, with a visual FDG uptake score of 4 (i.e., lesion
FDG uptake higher than liver FDG uptake) considered to
indicate malignancy and visual FDG uptake scores of 1 to 3
(i.e., lesion FDG uptake equal to or less than liver FDG up-
take) considered to indicate benignancy. In addition, receiver
operating characteristic curve analyses were done to calculate
the areas under the curve (AUC) of the semiquantitative
metrics SUVmax and SUVpeak. Furthermore, the following
variables were compared between malignant and benign ver-
tebral bone lesions: patient age, patient gender, previous diag-
nosis of malignancy (before FDG-PET/CT and biopsy), re-
ported bone pain, reported weight loss, previously described
CT features, multiple bone lesions on FDG-PET/CT, and sus-
picious extraosseous lesions on FDG-PET/CT. These vari-
ables were analyzed using the Fisher exact test for binary data,
the Mann-Whitney U test for nongaussian continuous data,
and the unpaired t test for gaussian continuous data. Two-
tailed P values less than 0.05 were considered statistically
significant. Statistical analyses were executed using the
MedCalc statistical software version 18.5 (MedCalc, Ostend,
Belgium).
Results
Patients
Sixty-one patients underwent FDG-PET/CT within 60 days
before CT-guided biopsy of a vertebral bone lesion. Of all
the patients, only one experienced a complication: a pneumo-
thorax that was due to needle malpositioning. None of the 61
patients was biopsied because of the suspicion of
spondylodiscitis. Eight patients were excluded because the
nature of the vertebral lesion remained unclear despite biopsy
and follow-up (i.e., initial CT-guided biopsy results were in-
determinate for a specific diagnosis, subsequent tissue sam-
plings were not performed, and follow-up period was less than
1 year). Seven of these 8 patients either had a history of cancer
(rectal cancer (n = 2), breast cancer (n = 1), breast cancer, neu-
roendocrine tumor and lymphoma (n = 1), and myeloma (n =
1)) and/or were suspected to have active cancer disease. Fifty-
three patients (26 males and 27 females, with a median age of
61 years (age range, 3–79 years) at the time of biopsy)
remained and were included in the analysis. Forty-five pa-
tients (84.9%) had a diagnosis of malignancy before FDG-
PET and biopsy, as shown in Table 1. The indications for
FDG-PET/CTwere initial cancer staging (n = 20), general di-
agnostic problem solving (n = 9), cancer treatment response
assessment (n = 8), suspicion of recurrent cancer (n = 8),
restaging recurrent cancer (n = 7), primary tumor detection
(n = 1), and surveillance/follow-up imaging after cancer treat-
ment (n = 1). Note that one patient underwent FDG-PET/CT
for initial cancer staging and because of suspicion of recurrent
cancer at a later time point.
Vertebral bone lesions
Of the 53 patients included, two underwent biopsy of two
different vertebral bone lesions. For one of them, both biop-
sies were done in one session, while for the other, there was a
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time interval of 15 months between the two biopsy sessions.
Therefore, the total amount of biopsied vertebral bone lesions
was 55. Fifty lesions were located in the vertebral body, 2
lesions were located in the transverse spinous process, 2 le-
sions were located in the spinous process, and 1 lesion was
located in the superior articular process. Eighteen lesions were
at the thoracic level, 18 at the lumbar level, and 19 at the sacral
level. Median number of days between FDG-PET/CT and
biopsy was 12 days (range, 1–58 days). Forty-six vertebral
lesions proved to be malignant (all diagnoses based on the
CT-guided biopsy sample), and 9 lesions proved to be benign
(all diagnoses based on a negative biopsy for malignancy and
subsequent clinical and imaging follow-up). The nature of all
vertebral bone lesions is shown in Table 2.
Diagnostic value FDG-PET
Sensitivity, specificity, PPV, and NPVof visual FDG-PET/CT
analysis in discriminating malignant from benign vertebral
bone lesions were 91.3% (42/46), 22.2% (2/9), 85.7% (42/
49), and 33.3% (2/6), respectively. The semiquantitative
FDG-PET metrics SUVmax and SUVpeak achieved AUCs of
0.630 (95% confidence interval (CI), 0.490–0.757) and 0.671
(95% CI, 0.532–0.792), respectively. Corresponding ROC
curves are shown in Fig. 1. Representative case examples
are shown in Figs. 2, 3, and 4.
Diagnostic value of clinical and conventional imaging
characteristics
Bone lysis was more frequently observed in malignant verte-
bral bone lesions (60.9% (28/46)) than in benign vertebral
bone lesions (22.2% (2/9)), and this difference was nearly
significant (P = 0.064). All other clinical and conventional
imaging characteristics were not significantly different be-
tween malignant and benign vertebral bone lesions (P =
0.143 to 1.000), as shown in Table 3.
Table 2 Nature of 55 vertebral bone lesions
Nature of lesions Number of lesions
Malignant (n = 46)
Breast cancer 15
Lung cancer 12
Malignant lymphoma 3
Acute leukemia 2
Carcinoma of unknown primary 2
Esophageal cancer metastasis 2
Head and neck cancer metastasis 2
Myeloma/plasmacytoma 2
Chordoma 1
Ewing sarcoma 1
Melanoma metastasis 1
Neuroendocrine tumor metastasis 1
Renal cell cancer metastasis 1
Urothelial carcinoma metastasis 1
Benign (n = 9)
Benign, but exact nature unknown 6
Osteoporotic fracture 2
Spondylodiscitis (with atypical presentation)Z 1
Table 1 Types of cancer in 45
patients of 53 included patients
(84.9%) who had a diagnosis of
malignancy before FDG-PET and
biopsy
Types of cancer Number of patients
Breast cancer 16
Lung cancer 7
Malignant lymphoma 5
Esophageal cancer 3
Head and neck cancer 3
Cholangiocarcinoma 1
Chordoma 1
Gastrointestinal stromal cell tumor 1
Melanoma 1
Multiple myeloma 1
Prostate cancer 1
Rectal cancer 1
Thymic neuroendocrine tumor 1
Urothelial carcinoma 1
Breast cancer and malignant lymphoma 1
Malignant lymphoma, melanoma, and mesothelioma 1
Skeletal Radiol
Fig. 2 A 61-year-old man with a history of malignant lymphoma and
melanoma, in whom FDG-PET showed a lesion in the T4 vertebra (a,
arrow), also shown on low-dose CT (b, arrow). The lesion in the T4
vertebra had a visual FDG uptake higher than liver FDG uptake, an
SUVmax of 11.1, and an SUVpeak of 9.4. Prebiopsy planning CT showed
lysis, cortical destruction, and bone marrow replacement (c and d, ar-
rows). The biopsy needle traverses the location of the lesion in vertebra
T4 on CT (f). Pathologic examination revealed metastatic renal cell
cancer
Fig. 1 ROC curves of SUVmax
(a) and SUVpeak (b) in
discriminating malignant from
benign vertebral bone lesions.
AUCs were 0.630 (95% CI,
0.490–0.757) and 0.671 (95% CI,
0.532–0.792), respectively
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Discussion
This study aimed to elucidate the role of prebiopsy FDG-PET/
CT in characterizing vertebral bone lesions. Importantly, the
fact that FDG-PET/CT was performed before biopsy in all
patients in this study implies that the observation of an
FDG-avid spinal lesion frequently prompted the clinical deci-
sion to perform a vertebral biopsy. Patients with FDG-
negative or low FDG-avid vertebral bone lesions (e.g., simple
hemangioma, bone island, or Schmörl’s node) that have char-
acteristic conventional imaging characteristics are usually not
selected to undergo vertebral biopsy and were hence not in-
cluded in the present study. This explains that 49 out of 55
vertebral bone lesions in this study had the highest visual FDG
uptake score (i.e., lesion FDG uptake exceeding liver FDG
uptake). However, this represents clinical practice, and the
included patients are those in whom improved noninvasive
lesion characterization is paramount. Since this results in a
natural overrepresentation of FDG-avid lesions compared
with FDG-negative or low FDG-avid lesions among the total
amount of biopsied vertebral bone lesions, PPV is the most
important diagnostic metric in this setting.
The results of our study show that FDG-PET/CTachieves a
fairly high, but not infallible PPV of 85.7% (95% CI, 80.7–
89.6%) in discriminating malignant from benign vertebral
bone lesions. This is in line with previous work that has shown
that there are several benign bone conditions that may be
FDG-avid and mimic malignancy, including (focal) red mar-
row hyperplasia [12]. Semiquantitative FDG-PET/CT
measurements had some value in differentiating malignant
from benign vertebral bone lesions, with AUCs of 0.630 and
0.671 for SUVmax and SUVpeak, respectively. Clinical and
other imaging findings did not prove to be diagnostically use-
ful, except that a lytic appearance tended to more frequently
occur in malignant than in benign vertebral bone lesions
(60.9% vs. 22.2%, respectively). Overall, FDG-PET/CT cer-
tainly has value in characterizing vertebral bone lesions.
However, for patients whose treatment decisions depend on
the nature of an FDG-avid vertebral lesion (as detected on
PET/CT), and SUV values are not in the very high range, it
is still advocated to perform a biopsy to confirm malignancy
and to rule out a benign cause. On the other hand, biopsy does
not always provide a definitive diagnosis. In the case of be-
nign vertebral lesions for instance, it is not infrequently diffi-
cult to establish a specific diagnosis based on a limited amount
of tissue obtained. Follow-up is then necessary to confirm
benignancy, as demonstrated in the present study. This indi-
cates the need for improved diagnostic tools, such as PET/
MRI, artificial intelligence-based methods, and perhaps
tumor-specific tracers, which should be the topics of further
research.
Some previous studies have investigated the value of FDG-
PET/CT for the characterization of bone lesions, with CT-
guided biopsy as reference standard [13–16]. In one of the
largest of these studies, Adams et al. [14] analyzed 94 patients
with bone lesions that exceeded liver FDG uptake. Bone bi-
opsy showed a malignant lesion in 83 patients, which
corresponded to a PPV for malignancy of 88.3% (95% CI,
Fig. 3 A 49-year-old man with a history of orthotopic liver transplanta-
tion because of alcoholic liver cirrhosis underwent FDG-PET because of
fever of unknown origin and pancytopenia. FDG-PET showed multiple
FDG-avid bone lesions, including involvement of several vertebrae (a
and b, arrowheads). There is preexistent enlargement of the spleen, with
diffusely increased splenic FDG uptake (a, asterisk). The lesion in verte-
bra S2 (a and c, arrows), with its anatomic location also shown on con-
comitantly acquired low-dose CT (d, arrow), was selected for CT-guided
biopsy. This lesion had a visual FDG uptake higher than liver FDG
uptake, an SUVmax of 16.5, and an SUVpeak of 8.0. Prebiopsy planning
CT (e) showed no structural abnormality. The biopsy needle traverses the
location of the lesion in vertebra S2 on CT (f). Pathologic examination
neither showed any signs of malignancy or infection, nor could establish
any other diagnosis. Follow-up FDG-PET 2 months later showed spon-
taneous resolution of all previously present FDG-avid bone lesions (g),
hemoglobin, leukocyte, and thrombocyte levels had increased, and no
malignancy or other active disease was diagnosed in the next 36 months.
Therefore, although the nature of the abnormality in vertebra S2 remained
unclear (with hyperplastic red bone marrow islands in the differential
diagnosis), it could be classified as benign
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80.1–93.5%) [14], which approaches the PPV found in the
present study. However, the study by Adams et al. [14] and
most other previous studies on this topic included patients
with bone lesions in all parts of the skeleton without a separate
analysis for vertebral lesions [13, 15, 16]. Since the spectrum
and incidence of diseases in the spine are different than in
other bones [3, 4], a separate analysis for vertebral bone le-
sions is required. Another study by Laufer et al. [17] evaluated
the accuracy of FDG-PET in the diagnosis of vertebral metas-
tases in 82 patients with previously diagnosed cancer, with
CT-guided biopsy as reference standard [17]. FDG-PET was
reported to have a PPV of 97.4% (95% CI, 93.4–99.0%) for
malignancy when considering all lesions with an SUVof 2.0
as malignant [17]. However, this very high PPV is subject to
inflation due to the fact that the SUVmax threshold of 2.0 was
retrospectively applied to the dataset. In addition, SUVmax
measurements were done by different readers (in part obtained
from the clinical radiology reports); it was not reported if these
measurements were performed in a blinded manner; an out-
dated non non-cross-calibrated stand-alone PET system was
Fig. 4 A 41-year-old man with multiple endocrine neoplasia type 1
underwent FDG-PET to monitor a known neuroendocrine tumor in the
pancreas and previously seen FDG-avid mediastinal lymph nodes. These
findings were stable on FDG-PET, but on the low-dose CT part of the
FDG-PET examination, a sclerotic lesion in the left dorsal T8 vertebra—
left pedicle—was seen, without any visual FDG uptake (a and c, arrows).
Corresponding SUVmax was 2.1 and SUVpeak was 1.1. The lesion is more
clearly visualized on prebiopsy planning CT (c and d, arrows). The biop-
sy needle is shown to traverse the location of the lesion in vertebra T8 on
CT (e). Pathologic examination revealed metastatic neuroendocrine
tumor
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used, and reconstructed images were not performed according
to EANM/EARL standards, which all shed doubts on the va-
lidity of their results.
The present study had several limitations. First, despite the
8-year inclusion period, the number of patients with benign
vertebral bone lesions was relatively low. This is due to the
general low incidence of benignancy in vertebral lesions that
are selected for biopsy, and the fact that several patients had to
be excluded because the nature of their vertebral lesions
remained unclear despite biopsy and follow-up. The majority
of patients (84.9%) had a medical history of cancer, which
limits the extent to which the conclusion of the study can be
applied to the general population. Nevertheless, to the best of
our knowledge, it is still the largest study on this topic so far.
Second, the results of this study are not applicable to the dif-
ferentiation between benign and malignant vertebral compres-
sion fractures, because only 10 of 55 included vertebral
lesions had accompanying vertebral height loss (of which only
4 with severe, more than 40%, height loss [18]), which did not
allow for a subanalysis. Third, this study was performed at a
tertiary care center in Europe, and the results may be different
in other institutions with different patient populations and with
different types of vertebral pathology. Fourth, the additional
value of MRI to FDG-PET (and vice versa) could not be
assessed, because only 19 of 55 lesions were imaged on
MRI. Fifth, no comparison was made with planar or
SPECT/CT bone scintigraphy. However, bone scintigraphy
reflects indirect evidence for disease as a result of reactive
bone formation after long-standing red marrow involvement
[19, 20]. In contrast, FDG-PET detects metastasis very early
on during the course of disease when it is confined to the bone
marrow [19, 20]. In addition, unlike bone scintigraphy, FDG-
PET allows for assessment of both skeletal and extraskeletal
lesions [19, 20]. Therefore, bone scintigraphy has important
Table 3 Comparison of patient
and conventional imaging
characteristics between malignant
and benign vertebral bone lesions
Characteristic* Malignant Benign P value
Age (years), median 61a 65a 0.265b
Male sex 23/46
(50.0%)
5/9
(55.5%)
1.000c
Previous diagnosis of malignancy 38/46
(82.6%)
7/9
(77.7%)
0.661c
Bone pain 19/46
(41.3%)
4/9
(44.4%)
1.000c
Weight loss 5/46
(10.9%)
2/9
(22.2%)
0.321c
CT abnormality (any) 37/46
(80.4%)
6/9
(66.7%)
0.392c
CT lysis 28/46
(60.9%)
2/9
(22.2%)
0.064c
CT sclerosis 19/46
(41.3%)
5/9
(55.5%)
0.482c
CT cortical destruction 29/46
(63.0%)
3/9
(33.3%)
0.143c
CT bone marrow replacement 17/46
(37.0%)
2/9
(22.2%)
0.473c
CT associated soft tissue mass 10/46
(21.7%)
2/9
(22.2%)
1.000c
CT accompanying vertebral height loss 8/46
(17.4%)
2/9
(22.2%)
0.661c
Multiple bone lesions on FDG-PET/CT 26/46
(56.5%)
4/9
(44.4%)
0.716c
Suspicious extraosseous lesions on FDG-PET/CT 33/46
(71.7%)
5/9
(55.5%)
0.435c
Glucose corrected SUVmax, median 10.0
a 6.0a 0.219b
Glucose corrected SUVpeak, median 8.1
a 4.4a 0.106b
* Patient and imaging characteristics corresponding to each of 55 separately biopsied vertebral bone lesions
a Not normally distributed according to Shapiro-Wilk test
bMann-Whitney U test
c Fisher exact test
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limitations. In our study population, only 4 patients have also
undergone bone scintigraphy before FDG-PET/CT.
In conclusion, FDG-PET/CT may steer the diagnosis (par-
ticularly thanks to a relatively high PPV and value of semi-
quantitative measurements), but cannot always classify verte-
bral bone lesions as malignant or benign with sufficient cer-
tainty. In these cases, biopsy and/or follow-up remain neces-
sary to establish a final diagnosis.
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